DIO Corporation (KOSDAQ:039840)
South Korea
· Delayed Price · Currency is KRW 16,040
-710 (-4.24%)
Mar 9, 2026, 3:30 PM KST
DIO Corporation Revenue
DIO Corporation had revenue of 41.45B KRW in the quarter ending September 30, 2025, with 32.23% growth. This brings the company's revenue in the last twelve months to 155.15B, up 37.84% year-over-year. In the year 2024, DIO Corporation had annual revenue of 119.65B, down -23.21%.
Revenue (ttm)
155.15B
Revenue Growth
+37.84%
P/S Ratio
1.38
Revenue / Employee
323.91M
Employees
479
Market Cap
214.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.65B | -36.17B | -23.21% |
| Dec 31, 2023 | 155.82B | 24.51B | 18.67% |
| Dec 31, 2022 | 131.31B | -18.73B | -12.48% |
| Dec 31, 2021 | 150.04B | 29.98B | 24.97% |
| Dec 31, 2020 | 120.06B | -7.11B | -5.59% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,556.97B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| Sam Chun Dang Pharm. | 220.74B |
| EASY BIO,Inc. | 465.24B |
| Chong Kun Dang Holdings | 950.10B |
| Genexine | 5.81B |
| Daewon Pharmaceutical | 590.70B |